The SoftBank-backed genetic liquid biopsy technology developer has raised a nine-figure renminbi amount in a Shenzhen Capital-led round.
HaploX, a China-based genetic sequencing technology provider backed by telecoms group SoftBank, has raised a nine-figure renminbi sum (RMB100m = $15m) in a series B round featuring, China Money Network reported yesterday.
The round was led by Shenzhen Capital Group, the venture capital firm founded by the city of Shenzhen’s municipal government.
Founded in 2014, HaploX is developing liquid biopsy technology that will make use of genetic sequencing, artificial intelligence and big data to help treat cancer patients by assessing…
